We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.
International public health has begun to pay significant attention to the substantial morbidity and death caused by the monkeypox virus in humans. Therefore, it is essential to develop effective strategies for controlling and transmission of the virus. Creative Biolabs has been engaged in the antibody industry for more than ten years, offering a complete spectrum of monoclonal antibody antiviral drug development solutions. In the near future, the development of potential therapeutic approaches based on neutralizing antibodies against monkeypox could be effective in controlling the spread and infection of the monkeypox virus.
Neutralizing antibodies are a part of the humoral response of the adaptive immune system generated and secreted by B cells that specifically bind to the pathogens or infectious viruses and protect cells from them by neutralizing their biological effects. The neutralization makes the pathogens or infectious viruses no longer pathogenic or infectious.
A virus's lifecycle involves attachment, entry, replication, proteolytic processing, and particle egress steps. Leveraging the mechanism of neutralizing antibodies, the virus entry into the host cells could be prevented by binding to the neutralizing antibodies. The infectious virus lifecycle initiates from the entry by the interaction and recognition of the viral proteins with the host cell surface receptors. Neutralizing antibodies have the ability to inhibit the viral infection by binding to the viral protein and block the entry. Monkeypox is an enveloped double-stranded DNA virus. Neutralizing antibodies could therefore bind to glycoproteins of enveloped monkeypox to prevent the entry of monkeypox viruses into the human host cells. In addition, neutralizing antibodies may prevent conformational changes of viral proteins that are needed for the entry and induce macrophage degradation of the virus-antibody complex. However, due to the high mutation rate of the viral genome, the virus can evade recognition by neutralizing antibodies. The key is to identify the conserved core protein of the monkeypox, in order to improve the neutralizing antibody recognition of viral particles. For this purpose, Creative Biolabs offers professional neutralizing antibody-based anti-monkeypox drug discovery solutions for research from mechanism to clinical translational application.
Creative Biolabs offers a full range of neutralizing antibody-based anti-monkeypox drug discovery solutions to explore specific and robust neutralizing antibody therapeutics against monkeypox. Our sophisticated high-throughput screening, artificial intelligence, in vitro and in vivo platforms, and monkeypox detection services help global customers to find anti-monkeypox solutions as expeditious as possible. We provide solutions to develop reliable purified polyclonal antibodies with low batch-to-batch variation, which can bind to multiple epitopes of the monkeypox virus to cope with the viral genomic variations. We also offer solutions to discover more specific monoclonal neutralizing antibodies that bind to a conserved epitope of the monkeypox virus. One of the advantages of monoclonal neutralizing antibodies against the monkeypox virus is the use of the hybridoma technique, which allows for the mass production of monoclonal neutralizing antibodies.
If you have the intention to customize the neutralizing antibody-based anti-monkeypox drug discovery solutions, please do not hesitate to contact us.
We DO NOT PROVIDE ANY PRODUCTS OR SERVICES DIRECTLY TO PATIENTS. All of our products are for Research Use Only (RUO), NOT intended for diagnostic, therapeutic, or clinical use.